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Abstract: Ceftobiprole, a new broad spectrum, parenteral cephalosporin, exhibits potent in vitro 
activity against a number of Gram-positive pathogens, including methicillin-resistant Staphylo-
coccus aureus and penicillin-resistant Streptococcus pneumoniae, and Gram-negative pathogens 
associated with hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP). 
Ceftobiprole has demonstrated noninferiority in two large-scale pivotal studies comparing it to 
ceftriaxone with or without linezolid in CAP, with clinical cure rates 86.6% versus 87.4%, or 
ceftazidime in HAP, with clinical cure rates of 77% versus 76%, respectively. However, cefto-
biprole was inferior in the subgroup of patients undergoing mechanical ventilation. Ceftobiprole 
has so far demonstrated a good safety profile in preliminary studies, with similar tolerability to 
comparators. The most commonly observed adverse events of ceftobiprole included headache 
and gastrointestinal upset. It is the first cephalosporin monotherapy approved in the EU for the 
treatment of both CAP and HAP (excluding ventilator-associated pneumonia).
Keywords: antibiotic resistance, methicillin-resistant staphylococci, community-acquired 
pneumonia, hospital-acquired pneumonia, cephalosporins
Introduction
Community-acquired pneumonia (CAP) is a significant cause of morbidity and 
mortality in developed countries, accounting for a considerable number of hospital 
admissions, especially in the elderly.1,2 Hospital-acquired pneumonia (HAP) is asso-
ciated with significant mortality and has been reported to account for .25% of all 
infections in intensive care units.3 HAPs dramatically increase both the hospital length 
of stay and the cost of care, and are associated with an overall mortality of 27%–51%,4 
the poorer prognosis being reported in the elderly.
The most common bacteria causing CAP are Streptococcus pneumoniae, Haemo-
philus influenzae, and Moraxella catarrhalis,1,2 and the most common bacteria causing 
HAP are Enterobacteriaceae (such as Klebsiella spp., Enterobacter spp., Serratia spp.), 
Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii.4,5 
S. aureus is the predominant Gram-positive pathogen in HAP and ventilator-associated 
pneumonia (VAP).
Pathogens that are resistant to antibacterials, particularly methicillin-resistant 
S. aureus (MRSA) and multidrug-resistant (MDR) S. pneumoniae, are associated with 
poor outcomes and higher treatment cost.6 Presently, half of the deaths from clinical 
infection in Europe are associated with MDR bacteria.7,8 Despite a decrease in the 
incidence of MRSA infections in recent years, the proportion of S. aureus isolates 
reported as MRSA in 2012 was $25% in seven of 30 European countries that pro-
vided surveillance reports.9 Koulenti et al10 reported that MRSA was isolated in 16% 
of patients with nosocomial pneumonia (21.4% in HAP and 14.6% in VAP). A large, 
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prospective study reporting 474 patients with VAP in Spain 
found that patients with MRSA VAP had significantly higher 
in-hospital mortality than patients with VAP caused by other 
microorganisms (59.5% versus 46.8%; P=0.02).11
The adequacy of empirical antimicrobial therapy is 
strongly predictive of hospital survival,3–5 making the 
definition of patients at risk for MDR pathogens a pivotal 
challenge.
Now with ceftaroline-fosamil and ceftobiprole, a new 
subclass of antimicrobials, cephalosporins with anti-MRSA 
activity has been introduced. Ceftobiprole medocaril is a 
newly approved drug in Europe for the treatment of CAP and 
HAP (excluding patients with VAP) in adults. This review 
focuses on the pharmacological properties of ceftobiprole 
and its clinical efficacy and tolerability in adult patients with 
CAP and HAP.
Mechanism of action and 
antimicrobial activity
Ceftobiprole medocaril is the prodrug form of ceftobiprole, 
which is an extended-spectrum cephalosporin that encom-
passes activity against both Gram-positive and most Gram-
negative bacteria, including MRSA. It has bactericidal effects 
against community-acquired MRSA, vancomycin-resistant 
S. aureus, methicillin-resistant coagulase-negative staphy-
lococci (CoNS), penicillin-resistant S. pneumoniae, Entero-
coccus faecalis, Clostridium perfringens, P. aeruginosa, and 
85% of Enterobacteriaceae.12,13 (Figure 1)
Like other cephalosporins, the binding of ceftobiprole to 
penicillin-binding proteins (PBPs) interferes with cell wall 
synthesis, inhibiting cell growth and ultimately leading to 
bacterial cell death.
Ceftobiprole was refractory to hydrolysis by the com-
mon staphylococcal PC1 β-lactamase, the class A TEM-1 
β-lactamase, but labile to hydrolysis by class B, class D, 
and class A extended-spectrum β-lactamases, thus similar to 
cefepime and ceftazidime patterns of action.14 Ceftobiprole 
is relatively stable toward AmpC β-lactamases and has a 
strong affinity for PBPs, including PBP 2A, which mediates 
resistance to β-lactams in MRSA and methicillin (oxacillin)-
resistant CoNS.15
It has high affinity against S. pneumoniae PBP 2× in 
penicillin-resistant and ceftriaxone-resistant strains and 
retains good in vitro activity against them.16,17 In a study by 
Kosowska et al18 testing its in vitro activity, Ceftobiprole 
minimum inhibitory concentrations (MICs) were similar 
to those of carbapenems against nearly all pneumococcal 
strains tested. Ceftobiprole was especially active against 
299 drug-susceptible and -resistant pneumococci, with 
MIC of 50% (MIC
50
) and 90% (MIC
90
) values of 0.016 
and 0.016 μg/mL (penicillin-susceptible isolates), 0.06 and 
0.5 μg/mL (penicillin-intermediate isolates), and 0.5 and 1.0 
μg/mL (penicillin-resistant isolates), respectively. Interest-
ingly, during 50 serial passages in the presence of subinhibi-
tory concentrations of antibiotics, the highest MIC achieved 
for ceftobiprole by a panel of ten pneumococcal isolates was 
1 μg/mL.18
From the ceftobiprole SENTRY Antibiotic Surveillance 
Program in Europe (2005–2010), ceftobiprole continues 
to demonstrate high potency against the causative agents 
of CAP, with 99.3% of 4,443 S. pneumoniae isolates test-
ing susceptible, as well as 2,052 strains of H. influenzae 
inhibited at MIC values of ,0.5 μg/mL and 200 strains of 
M. catarrhalis inhibited at MIC values of ,0.5 μg/mL.15 
A 2008 US surveillance study on S. pneumoniae called, 
TRUST 12, showed that ceftobiprole was the most potent 
cephalosporin tested against S. pneumoniae with MIC
50
 
(0.015 μg/mL) and MIC
90
 (0.5 μg/mL), with values two-fold 
lower than ceftriaxone.16
However, it is the bactericidal activity against MRSA 
that sets ceftobiprole apart from other cephalosporins.12 
In time-kill analysis, ceftobiprole was bactericidal against 
community-acquired and hospital-acquired MRSA 
strains.19,20 In the SENTRY study, 4,147 of 15,426 (26.9%) 
S. aureus clinical isolates collected from Europe, Turkey, 
and Israel during 2005–2010 were MRSA, and 98.3% of 
these strains were susceptible to ceftobiprole.15 Moreover, 
ceftobiprole demonstrates in vitro activity against S. aureus 
resistant to linezolid, vancomycin, and daptomycin and 
ceftriaxone-resistant S. pneumonia.16,17,21 The CLASS study, 
evaluating the in vitro activity of ceftobiprole, published by 
Rossolini et al22 across 19 countries, further demonstrates 
the activity of ceftobiprole against all linezolid nonsuscep-
tible staphylococcal isolates; a significant finding in light 
of recent reports of linezolid-resistant MRSA and CoNS 
strains.
Ceftobiprole also displayed bactericidal activity against 
Gram-negative pathogens comparable to cefepime, cef-
tazidime, or piperacillin-tazobactam in early studies.23,24 
The SENTRY surveillance study,15 published in 2014, 
showed activity against P. aeruginosa (64.6% susceptible 
by the European Committee on Antimicrobial Susceptibil-
ity Testing nonspecies-specific susceptibility breakpoint 
of 4 μg/mL) that was lower than but similar to those of 
cefepime (78.6% susceptible) and ceftazidime (75.4% 
susceptible).
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It has only moderate activity against Acinetobacter spp.
and is not active against Proteus vulgaris, ceftazidime-
nonsusceptible P. aeruginosa, Bacteroides spp., and some 
extended-spectrum β-lactamase-producing isolates.
Ceftobiprole has limited activity against Gram-negative 
anaerobes such as Bacteroides fragilis and non-fragilis 
Bacteroides spp. but is generally active against Clostridium 
spp. and Fusobacterium spp. (MIC
90
 8 mg/L).25,26
Pharmacokinetic/pharmacodynamic 
(PK/PD) profile
Like other β-lactams, ceftobiprole exhibits concentration-
independent killing; studies in animals and of in vitro PK 
models have shown that the duration that the unbound 
concentration of an antibiotic remains above the MIC as a 
percentage of the dosing interval (%fT . MIC) is the PK/PD 
index that best correlates with drug-related response.
Muller et al27 using data from a randomized double-blind 
Phase III clinical trial, explored the relationship of ceftobi-
prole exposure with microbiological and clinical outcomes 
in patients with nosocomial pneumonia. According to regres-
sion analyses, a significant (P=0.0029) correlation was seen 
between %fT . MIC and clinical cure when %fT . MIC 
was .51.1%; a significant (P.0.0001) correlation was also 
observed for microbiological eradication when %fT . MIC 
was .62.2%.
Single- and multiple-dose PKs of ceftobiprole have been 
evaluated in healthy volunteers.28 With ceftobiprole 500 mg 
every 8 hours infused over 2 hours, the probability of attain-
ing a 50% fT . MIC target was 80% for an MIC of 4 mg/L 
in subjects with normal renal function and 98.8% and 99.9% 
for MRSA and methicillin-sensitive S. aureus, respectively, 
with MIC
90
 1 and 0.5 mg/L, respectively.29
Utilizing Monte Carlo simulations, the probability of 
target attainment corresponding to 60% fT/MIC for cefto-
biprole 500 mg every 8 hours (2-hour infusion) is 87.8% 
for AmpC-producing bacilli, with an MIC
90
 of 16 μg/mL 
and 94.1% for non-AmpC-producing bacilli for an MIC
90
 
of ,0.25 μg/mL.28,29
Peak levels of the active drug in plasma were achieved at 
the end of the 30-minute infusion. The apparent volume of 
distribution was similar to those reported to other β-lactams 
(18–20/L). Ceftobiprole demonstrates a low percentage of 
protein binding (16%)13 and is independent of the drug con-
centration across the range of 0.5–100 μg/mL. Renal clear-
ance and urinary excretion of the free drug decreased while 
the elimination half-life increased with decreasing renal func-
tion. Patients with a creatinine clearance of 30,50 mL/min 
should have the dosing interval adjusted to every 12 hours. 
In patients with a creatinine clearance ,30 mL/min, the 
dosing regimen should be 250 mg every 12 hours as a 2-hour 
intravenous infusion.13,19,29,30
Ceftobiprole exhibits a modest postantibiotic effect 
(30 minutes) for MRSA and a more prolonged postantibiotic 
effect (2 hours) for penicillin-resistant pneumococci.31
It does not inhibit the cytochrome P-450 isoenzyme sys-
tem, so the possibility of drug–drug interactions is low.
Clinical efficacy in pneumonia
Because of its broad-spectrum activity against lower respi-
ratory tract pathogens, ceftobiprole was evaluated in the 
treatment of CAP and HAP.
Clinical trials in CAP
Firstly, in a study conducted to compare the in vivo activity 
of ceftobiprole with that of ceftriaxone in a mouse model of 
acute pneumococcal pneumonia there was no significant dif-
ference in cumulative survival rates between the two antibiot-
ics, but 100% survival was obtained at a five-fold lower total 
daily ceftobiprole dose than the dose of ceftriaxone used.32
The clinical efficacy of ceftobiprole in CAP demonstrated 
by the results of a randomized, double-blind, comparative 
study of ceftobiprole medocaril (500 mg every 8 hours 
infused over 2 hours) versus ceftriaxone (2 g once daily as 
30-minute infusions) with or without linezolid (600 mg every 
12 hours as 1-hour infusions, 7–14 days) in the treatment 
of subjects hospitalized with CAP.33 By the study design, 
linezolid was allowed for subjects with proven or suspected 
MRSA or ceftriaxone-resistant S. pneumoniae. Patients 
were stratified before randomization based on the Pneumo-
nia Patient Outcomes Research Team (PORT); Pneumonia 
Severity Index (PSI), corresponding to class IV and V sever-
ity, and need for addition of linezolid versus placebo. If after 
day 3, patients met stability criteria, they were eligible to 
switch to oral cefuroxime 500 mg every 12 hours.
A typical bacterial pathogen was isolated at baseline in 
28.8% of the intention-to-treat (ITT) population, with S. pneu-
moniae (n=68) and H. influenzae (n=26) being the most com-
mon. The ceftobiprole group had more polymicrobial infection 
than did the comparator group (20% versus 8%, P=0.016).
The severity of pneumonia at baseline had no effect on 
clinical cure rates at the test of cure visit between the two 
groups.
For the 469 clinically evaluable (CE) patients, cure rates 
were 86.6% versus 87.4% for ceftobiprole and comparator, 
respectively; in the ITT analysis of 638 CAP patients, these 
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cure rates were 76.4% versus 79.3%, respectively, dem-
onstrating the noninferiority of ceftobiprole compared to 
ceftriaxone in CAP therapy.
For the secondary end-point of clinical cure in patients 
with a pneumonia severity index $91, the cure rates for 
the above regimens were 90.2% and 84.5% compared with 
85.6% and 88.3% for those with lower scores, respec-
tively. In patients with CAP complicated by bacteremia, 
cure rates were 85.7% versus 85.7%; and with presence of 
systemic inflammatory response syndrome 84.6% versus 
86.7% for ceftobiprole and ceftriafone linezolid therapy, 
respectively.
Referring to the secondary efficacy endpoint of microbio-
logical eradication, noninferiority between the ceftobiprole 
and comparator groups was observed also. Subgroup analyses 
showed that among those who switched to oral cefuroxime, 
microbiological eradication rates were significantly lower 
with ceftobiprole medocaril than with ceftriaxone ± linezolid 
(89% versus 100%; n=37 and n=41, respectively).
Clinical trials in HAP
A Phase III randomized double-blind study was designed to 
compare the ceftobiprole medocaril (500 mg every 8 hours, 
infused over 2 hours) versus linezolid (600 mg every 
12 hours as a 1-hour intravenous infusion) plus ceftazidime (2 g 
every 8 hours as a 2-hour intravenous infusion) for 7–14 days 
in 781 recruited subjects with clinical diagnosis of HAP, 
including VAP.34
The overall cure rates in the ITT population were 50% for 
ceftobiprole and 52.8% for combination therapy, and in the 
CE population, 69.3% in the ceftobiprole group and 71.6% 
demonstrating the noninferiority of ceftobiprole compared 
to the comparator group.34
Among patients without VAP, the cure rate in the ITT 
population was 77.4% in the ceftobiprole group and 76.3% 
in the comparator group, and in the CE population, it was 
38.5% and 56.7%, respectively.
In the CE analysis set, a higher proportion of HAP 
(excluding VAP) patients in the ceftobiprole group than in 
the ceftazidime/linezolid group (CE, 86.9% versus 78.4%, 
respectively) showed early improvement (4 days after onset 
of therapy) (Table 1). The largest difference was for patients 
with a baseline culture positive for MRSA, with 94.7% in the 
ceftobiprole group having early improvement versus 52.6% 
in the ceftazidime/linezolid group (difference, 42.1%).35
The overall microbiological eradication rate in the 
ceftobiprole group was 62, 9% (73/116) compared to 67, 
5% (81/120) in the ceftazidime/linezolid group. However, 
subjects with clinical cure 73/86 (85%) in the ceftobiprole 
group and 81/94 (86%) in the other group, had an outcome 
of microbiological eradication.
Of note, in patients with non-VAP, clinical cure rates 
were similar between ceftobiprole medocaril and ceftazidime 
plus linezolid recipients who had P. aeruginosa at baseline. 
Only for A. baumannii and Haemophilus spp. were numeri-
cally lower clinical cure and microbiological eradication 
rates observed in the ceftobiprole group.
Thirty-day pneumonia-specific mortality was similar 
between the two treatment groups, 5.9% and 5.6%, respec-
tively (difference, 0.3%).
However, ceftobiprole was inferior in the subgroup 
of patients with VAP.13,34 The clinical cure rate in the CE 
Figure 1 The chemical structure of ceftobiprole.
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population with VAP favored the linezolid/ceftazidime arm 
over the ceftobiprole arm, 56.7% versus 38.5%, respectively 
(P,0.05). Interestingly, in mechanically ventilated patients 
with non-VAP, clinical outcomes were in favor of cefto-
biprole medocaril, suggesting that mechanical ventilation 
by itself is not associated with poor outcomes. In fact, of 
the 16 VAP patients #45 years with head trauma that were 
randomized to ceftobiprole, 12 were characterized as treat-
ment failures compared to two out of the four assigned to 
the linezolid/ceftazidime group.
There are different explanations for this result: 1) It is 
thought by the authors that the small sample size and the 
substantial heterogeneity in baseline characteristics in the 
VAP subgroup may have contributed to the differential 
outcomes,34 and 2) the inferior outcome may have been the 
consequence of suboptimal concentrations of ceftobiprole 
at the site of infection, as a result of a change in the vol-
ume distribution owing to capillary leak from mechanical 
ventilation.36
In a more recent review,37 it was reported that in patients 
with normal PK and non-VAP, ceftobiprole is effective 
for the treatment of HAP in the recommended doses, but 
it is unlikely to achieve the desired PD targets when PK 
parameters are altered in VAP (eg, increased volume of distri-
bution and clearance). Consequently, ceftobiprole medocaril 
is not approved for patients with VAP.
Tolerability
Ceftobiprole medocaril is generally well tolerated in patients 
with HAP or CAP in Phase III trials.33,34 The incidence of 
serious adverse events (AEs) in ceftobiprole medocaril versus 
comparator groups were 36.3% versus 31.9% in the HAP trial 
and 11.3% versus 11.5% in the CAP trial, respectively.38
The most common treatment-related AEs occurring in 
ceftobiprole recipients in the trials in patients with HAP 
or CAP included nausea, dysgeusia, diarrhea, infusion site 
reactions, vomiting, hepatic enzyme elevations, and hypona-
tremia (Table 2).
Particularly in the Nicholson et al trial,33 in patients with 
CAP the overall incidence of treatment-related AEs was higher 
in the ceftobiprole group, primarily owing to differences in 
rates of self-limited nausea and vomiting. There were no dif-
ferences between groups for injection-site AEs, hyponatremia, 
or hepatic AEs.
Table 1 Efficacy of intravenous ceftobiprole medocaril in adult patients with HAP or CAP
Parameter CAP33 HAP34 VAP34
Drugs BPR
n=314
CRO + LZN
n=324
BPR
n=391
CAZ + LZN
 n=390
BPR
n=104
CAZ + LZN
n=106
Clinical cure
iTT, % (n) 76.4 (240) 79.3 (257) 49.9 (195) 52.8 (206) 23.1 (24) 36.8 (39)
Ce, % (n) 86.6 (200) 87.4 (208) 69.3 (174) 71.3 (174) 37.7 (20) 55.9 (33)
Microbiological eradication
iTT, % (n) 80.5 (70) 81.4 (79) 39 (105) 47.6 (127) 20 (18) 35 (30)
Me, % (n) 88.2 (60) 90.8 (69) 53.7 (87) 62.4 (106) 30 (14) 50 (25)
Abbreviations: BPR, ceftobiprole; CAP, community-acquired pneumonia; CAZ, ceftazidime; Ce, clinically evaluable; CRO, ceftriaxone; HAP, hospital-acquired pneumonia; 
iTT, intent-to-treat; LZN, linezolid; Me, microbiologically evaluable; vAP, ventilator-associated pneumonia.
Table 2 Safety profile of ceftobiprole in clinical trials of CAP and HAP
Adverse events CAP33 HAP34
Ceftobiprole CRO + LZN Ceftobiprole CAZ + LZN
Ae 70% 64.6% 77.5% 77.7%
One Ae 36% 26% 25% 25%
Serious Ae 11.3% 11.5% 36.3% 31.9%
Nausea 7% 2% 2.1% 2.1%
vomiting 5% 2% 1.6% 0.8%
Diarrhea 0 0 3.1% 6.5%
Anemia 0 0 5% 5%
Hepatic enzyme elevations 7% 7% 0.8% 1%
infusion site reactions 7% 5% 2.1% 1.3%
Hyponatremia 1% 3% 4.4% 2.6%
Dysgeusia 0 0 1.3% 0
Abbreviations: Ae, adverse events; CAP, community-acquired pneumonia; CAZ, ceftazidime; CRO, ceftriaxone; HAP, hospital-acquired pneumonia; LZN, linezolid.
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In the Awad et al HAP study,34 ceftobiprole patients 
had fewer treatment-related events of diarrhea than patients 
treated with ceftazidime/linezolid (3.1% and 6.5%, respec-
tively), whereas hyponatremia was observed more frequently 
with ceftobiprole than with ceftazidime/linezolid (4.4% and 
2.6%, respectively).
One study found that the most common patient complaint 
was “caramel-like taste disturbances” (dysgeusia) when the 
medication was administered at higher doses. This was found 
to be most likely a result of the metabolism of ceftobiprole 
medocaril to diacetyl.28
The drug is contraindicated in patients with severe hyper-
sensitivity (eg, anaphylactic reaction) to any other type of 
β-lactam antibacterial agent.
Regulatory affairs
Following approval under the European decentralized proce-
dure, ceftobiprole has received national licenses in Austria, 
Belgium, Denmark, Finland, France, Germany, Norway, 
Spain, Sweden, and the United Kingdom; national autho-
rization in Italy and Luxembourg; and reimbursement and 
pricing authorization in several countries including Spain is 
ongoing.39 It is also in preregistration stage in Switzerland 
for these indications.
Basilea Pharmaceutica Ltd. entered into an agreement 
with Quintiles in July 2014 for commercialization in key 
European countries of Zevtera®/Mabelio® (ceftobiprole 
medocaril) for patients with HAP and CAP.
In November 2008, the US Food and Drug Administra-
tion (FDA) declined to approve ceftobiprole, citing data 
integrity concerns with two of the supporting studies. The 
FDA determined that data from the two mentioned studies 
(BAP00154 and BAP00414) could not be relied on; inspec-
tions and audits of approximately one third of the clinical 
trial sites found the data from a large proportion of these sites 
to be unreliable or unverifiable.40
Expert opinion
One of the main challenges in the management of HAP and 
CAP is to overcome the resistance issues, which have become 
so important and common over the past several years. Manage-
ment of pulmonary infections caused by resistant Gram-positive 
pathogens, particularly MRSA, remains a significant challenge. 
An analysis of pneumococcal resistance rates in the US span-
ning the years 1998 to 2009 demonstrated remarkable increases 
in nonsusceptibility to commonly used β-lactam agents.41
Treatment guidelines for HAP recommend rapid empiric 
therapy with combinations of antibiotics based on local 
resistance patterns and patient risk factors.4 It has been rec-
ommended that initial empirical monotherapy should be used 
whenever possible to reduce the risk of MDR development 
and adverse outcomes.
Cephalosporins are effective first-line therapies for 
many bacterial infections. Ceftobiprole, a new parenteral 
cephalosporin has notable activity against Gram-positive 
pathogens, including MRSA, and some major Gram-negative 
pathogens, particularly P. aeruginosa. It was shown to be 
noninferior to ceftazidime plus linezolid for the treatment of 
HAP and ceftriaxone ± linezolid for the treatment of CAP (in 
hospitalized patients) in two randomized clinical trials.33,34
Regarding, clinical efficacy in CAP treatment, further 
studies are needed to determine the efficacy of ceftobiprole 
in more severely ill CAP patients.
Alternatively, the inferiority of ceftobiprole to linezolid 
plus ceftazidime in the treatment of VAP raises serious concern 
about the efficacy of the drug in achieving adequate concentra-
tions in the alveolar compartment of ventilated patients. We 
believe that if a larger dose of ceftobiprole had been used, the 
results might have been different. After all, a dose of 1,000 mg 
every 8 hours has been well tolerated in healthy volunteers.42 
Therefore, further investigation assessing the efficacy of cefto-
biprole medocaril in patients with VAP may be warranted.
Although ceftobiprole was not shown to induce resistance 
in clinical trials, recent studies demonstrate that low- and high-
level ceftobiprole resistance develop when isolates are exposed 
to sub-MIC concentrations.43 As with other cephalosporins, 
ceftobiprole may lose activity as the degree of expression of 
efflux pumps increases by bacteria such as Pseudomonas spp. 
Although it is impossible to know how quickly resistance to 
ceftobiprole will emerge in a clinical setting, the emergence 
of ceftobiprole resistance via chromosomal mutation was not 
readily observable in the laboratory.
Ceftobiprole medocaril is generally well tolerated in 
clinical trials, and 10% of patients discontinued the treatment 
because of AEs. Importantly, it has no significant impact on 
the normal human intestinal flora, and Clostridium difficile 
colitis is uncommon with ceftobiprole medocaril.44
Ceftobiprole offers a number of advantages in potency, spec-
trum, and β-lactamase stability compared to currently marketed 
third-generation carbapenems and other β-lactams. It may be a 
powerful antibiotic prescribed as monotherapy in serious CAP 
and HAP (excluding VAP) as initial empirical treatment.
Conclusion
Ceftobiprole is a new parenteral cephalosporin with bacte-
ricidal activity against Gram-positive pathogens including 
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MRSA, responsible for pneumonia, while preserving the 
anti-Gram-negative activity of existing broad-spectrum 
cephalosporins. Clinical data from two large Phase III studies 
have demonstrated that ceftobiprole medocaril is noninferior 
to the combination of high-dose ceftazidime and linezolid 
for the treatment of HAP (excluding VAP) and noninferior 
to high-dose ceftriaxone with or without linezolid for the 
treatment of CAP requiring hospitalization. Therefore cefto-
biprole represents a safe and effective treatment of hospital-
ized CAP and HAP (excluding VAP).
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